NASDAQ · Biotechnology

Larimar Therapeutics, Inc. (LRMR) Stock

$2.67 -1.11% NASDAQ: LRMR Healthcare

Valuation

MetricValue
Price$2.67
Market Cap$277.37M
P/E Ratio-1.49
P/B Ratio2.41
P/S Ratio0.00
EPS (TTM)$-2.27
52-Week High$6.42
52-Week Low$2.64
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-137.39%
ROA-104.42%
ROCE-136.49%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.04
Current Ratio2.18

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-50.0M$-37.0M$-42.0M$-91.0M$-172.0M
Net Profit$-51.0M$-35.0M$-37.0M$-81.0M$-166.0M
EPS$-2.93$-1.33$-0.84$-1.32$-2.27
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$79.0M$126.0M$96.0M$200.0M$146.0M
Total Liabilities$14.0M$16.0M$14.0M$28.0M$68.0M
Cash$70.0M$27.0M$27.0M$33.0M$85.0M
Borrowings$6.0M$5.0M$6.0M$5.0M$4.0M

Latest News

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy Insider Monkey · Jul 15, 2026 LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000 Stocktwits · Jul 8, 2026 Here’s What Citi Thinks About Larimar Therapeutics (LRMR) Insider Monkey · Jul 3, 2026 LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns Stocktwits · Jul 2, 2026 Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR) InvestorsHub · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-42.0M$-28.0M$-33.0M$-71.0M$-113.0M
Investing Cash Flow$24.0M$-91.0M$33.0M$-86.0M$100.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$2.0M$-43.0M$0$6.0M$52.0M
Free Cash Flow$-42.0M$-28.0M$-34.0M$-71.0M$-113.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.05
EV / EBITDA-1.28
FCF Yield-50.76%
Quick Ratio4.70
Interest Coverage0.00
Return 1Y6.65%
Return 3Y28.12%
Return 5Y-64.27%

Ownership

Insiders Held1.15%
Institutions Held86.19%
Institutions Float Held87.19%
Institutional HolderSharesReport Date
Deerfield Management Company, L.P35,606,9742026-03-31
Blue Owl Capital Holdings LP7,120,0072026-03-31
Blackrock Inc.3,752,2002026-03-31
Millennium Management Llc3,625,2782026-03-31
AIGH Capital Management LLC3,000,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACIUAC Immune SA $2.50 -1.96% -5.24 $254.43M 0.00%
ALTAltimmune, Inc. $2.61 +0.38% -3.42 $507.58M 0.00%
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
ANNXAnnexon, Inc. $4.02 +0.50% -3.61 $658.65M 0.00%
ANROAlto Neuroscience, Inc. $24.37 +1.41% -9.71 $855.24M 0.00%

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. is led by CEO Carole S. Ben-Maimon, employs 65 people, headquartered in US, publicly traded since 2014.

Larimar Therapeutics, Inc. (LRMR) stock trades at $2.67 with a market capitalization of $277.37M. The stock is valued at a price-to-earnings (P/E) ratio of -1.49, price-to-book of 2.41, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.64 and $6.42, and currently trades 58.4% below its 52-week high.

On profitability, Larimar Therapeutics, Inc. generates a return on equity (ROE) of -137.39%, return on capital employed of -136.49%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides